He will support efforts to take New Jersey's drug cost caps to the national level.

Herbert C. Conaway, Jr. · New Jersey · Democratic

policy impact 0.84 specificity 0.83 extraction confidence 95%

Contest this claim

Occurrences

Because these issues are so dear to my heart, I will support efforts that take New Jersey’s life-saving drug cost caps to the national level.

Promises to back federal prescription drug cost-cap efforts modeled on New Jersey policy.

Issues | Herb Conaway
campaign · campaign_site · model gpt-5.4-mini

Evidence

Sponsor: Rep. Conaway, Herbert C. [D-NJ-3] (Introduced 11/10/2025). Committees: House - Veterans' Affairs. Latest Action: House - 01/13/2026 Subcommittee Hearings Held. Committee activity is listed for 11/10/2025 referral, 11/17/2025 referral to the Subcommittee on Health, and 01/13/2026 hearings by the subcommittee.

Conaway advanced a veterans bill into subcommittee hearings, but it is not a prescription-drug cost-cap measure; the bill remains introduced and unpassed.

unresolved same_term A for effort

H.R.5999 - Committees | Congress.gov
secondary · model gpt-5.4-mini · confidence 78%

Contest this evidence item

Committee on Veterans’ Affairs: Full Committee held a markup on H.R. 5999, the 'Veteran Opioid Emergency Treatment Act' ... H.R. 5999 was ordered reported, as amended.

Within the lookback window, Conaway's bill moved through committee markup and was ordered reported, but the recorded measure is an opioid-antagonist access bill rather than a national prescription drug cost-cap bill.

unresolved same_term A for effort

Congressional Record Daily Digest, May 14, 2026 | GovInfo
secondary · model gpt-5.4-mini · confidence 83%

Contest this evidence item

Assessments

unresolved unknown

The provided evidence shows Conaway sponsored or advanced H.R. 5999, a veterans opioid emergency treatment/opioid-antagonist access measure, not a national prescription drug cost-cap bill modeled on New Jersey's drug cost caps. There is no evidence in the payload that he supported, sponsored, voted for, or materially advanced a federal drug cost-cap effort, and no evidence that such a national cap was enacted. Because the relevant promise-specific evidence is missing rather than clearly disproving any attempt, the claim remains unresolved rather than delivered or never.

provider codex_cli · model gpt-5.5 · confidence 78%